Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?

Executive Summary

The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.
Advertisement

Related Content

Economics Of Gaining Approval For Unapproved Phenylephrine Remains Question Mark
Bankrupt KV Pharma’s Hopes For Makena Rest With Skeptical Judge
Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
Makena Pricing Raises Ire Of Maternal Health Advocacy Groups
KV Readies For End-Of-March Makena Launch
Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants
NIH Will Not “March-In” On Pfizer’s Xalatan

Topics

Advertisement
UsernamePublicRestriction

Register

PS053233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel